Sanofi plans to continue distributing Zantac OTC heartburn remedy in the US while the firm conducts its own tests to determine whether levels of N-nitrosodimethylamine (NDMA) in the active ingredient ranitidine are above safe levels.
Novartis AG, which licenses OTC Zantac formulations (75- and 150-mg ranitidine) for US marketing to Sanofi while continuing to market the brand and to supply ranitidine for other firms in other countries, has said it stopped distribution of the